{"id":19580,"date":"2026-02-20T16:10:28","date_gmt":"2026-02-20T16:10:28","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/19580\/"},"modified":"2026-02-20T16:10:28","modified_gmt":"2026-02-20T16:10:28","slug":"novo-nordisk-nominates-jan-van-de-winkel-and-ramona-sequeira-to-board-2","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/19580\/","title":{"rendered":"Novo Nordisk nominates Jan van de Winkel and Ramona Sequeira to board"},"content":{"rendered":"<p class=\"mb-4 text-lg md:leading-8 break-words\">COPENHAGEN, Feb 20 (Reuters) &#8211; Novo Nordisk said on Friday it \u200cwould nominate Jan van de Winkel \u200cand Ramona Sequeira to its board of \u200bdirectors, the first additions since a shake-up at the Danish obesity drugmaker last year.<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">Novo Nordisk and its \u200cmajority shareholder, \u2060the Novo Nordisk Foundation, in 2025 replaced the drugmaker&#8217;s \u2060CEO and overhauled the board, installing Lars Rebien Sorensen who also \u200bchairs the \u200bFoundation, as \u200bboard chairman, giving \u200chim a powerful dual role.<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">Jan van de Winkel, co-founder and CEO of Genmab, was proposed for election at the annual general meeting to \u200cbe held on \u200bMarch 26, the \u200bWegovy-maker said \u200bin a statement.<\/p>\n<p>Advertisement<\/p>\n<p>Advertisement<\/p>\n<p>Advertisement<\/p>\n<p>Advertisement<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">Ramona Sequeira \u200cacted as President of \u200bthe Global \u200bPortfolio Division of Takeda Pharmaceutical Company Limited from 2022-2025, Novo \u200bNordisk said.<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">(Reporting \u200cby Stine Jacobsen and Louise \u200bRasmussen, editing by Terje Solsvik \u200band Mark Potter)<\/p>\n","protected":false},"excerpt":{"rendered":"COPENHAGEN, Feb 20 (Reuters) &#8211; Novo Nordisk said on Friday it \u200cwould nominate Jan van de Winkel \u200cand&hellip;\n","protected":false},"author":2,"featured_media":19495,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[13601,13538,13602,13603,13600,272,13539],"class_list":["post-19580","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-board-chairman","tag-jan-van-de-winkel","tag-lars-rebien-sorensen","tag-majority-shareholder","tag-nominate-jan-van-de-winkel","tag-novo-nordisk","tag-ramona-sequeira"],"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/19580","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=19580"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/19580\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/19495"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=19580"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=19580"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=19580"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}